Oncobiologics to price IPO of 5 million shares between $11.00, $13.00

Jefferies, Barclays are bookrunners; Cantor Fitzgerald is lead manager

By Devika Patel

Knoxville, Tenn., April 27 – Oncobiologics, Inc. will sell 5 million common shares in its initial public offering with a 30-day greenshoe of 750,000 additional shares, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The company has registered up to $74.75 million of stock for the deal, which was announced on Jan. 15.

The shares will be sold at a price expected to fall between $11.00 and $13.00 per share.

Jefferies LLC and Barclays are the bookrunners. Cantor Fitzgerald & Co. is the lead manager.

Proceeds will be used for clinical trials, research, working capital and general corporate purposes.

The biopharmaceutical company is based in Cranbury, N.J. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “ONS.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.